[Fine Chemicals] The 'sartan blood pressure drugs cause cancer' scandal is back—quick, check whether the medication you're taking is safe?
Back in 2018, China, Germany, Italy, Japan and other countries pulled large batches of valsartan from the market after valsartan API and finished valsartan products were found to contain a cancer-causing impurity. Now, the US, UK, Canada and others have once again recalled sartan drugs because they contain a 'carcinogenic' impurity.
Sartans are a common blood pressure medication in nephrology—almost every patient has taken one. So they cause cancer? What happened? Are sartans in China safe right now? We looked into the news as soon as it broke to share it with fellow kidney patients.
Drug regulators in several countries are requiring recalls of sartan drugs.
On April 29 this year, the European Directorate for the Quality of Medicines & HealthCare (EDQM) issued a notice saying a recent investigation found that sartan active pharmaceutical ingredients (APIs) contain an azide impurity that can be 'mutagenic.' It asked API manufacturers or their agents to handle the affected drugs as required, to keep azide impurity levels in the medicine below toxic doses.
Soon after, in May, Health Canada issued a notice recalling irbesartan, losartan and valsartan made by some manufacturers after testing found azide impurities above acceptable limits. It is also testing the recalled drugs to measure impurity levels and decide next steps.
After that, the UK and South Korea also recalled certain batches of irbesartan tablets to clarify the safety of the azide impurities. The US Commerce Department said it hopes drug companies will take the necessary steps to reduce or eliminate azide impurities in their products and will impose controls on the companies affected.
The drugs recalled this time involve different batches from dozens of pharmaceutical companies, including Sanofi, Novartis Sandoz, Teva, India's Sun Pharma, Pro Doc Ltd, Sivem Pharmaceuticals ULC, Mint Pharmaceuticals and Pharmascience.
This isn't the first recall.
This isn't the first time sartan drugs have been recalled over a 'carcinogenic' impurity.
In July 2018, the European Medicines Agency (EMA) issued a notice saying that after detecting the 'carcinogenic impurity' N-nitrosodimethylamine, it would review valsartan sold in Europe by Zhejiang Huahai Pharmaceutical. Germany, Italy, Finland, Austria, Japan and other countries then carried out recalls as well.
Comments
0